论文部分内容阅读
近年来随着介入放射学技术的发展，超选择性动脉内插管区域性治疗颅内恶性肿瘤包括颅内转移癌，目前已被广大患者接受。本技术不仅操作简单、创伤小，无论颅内肿瘤的部位深浅、大小、单发或多发、手术后复发及转移的病灶均适用。更重要的是我们将保尔佳及化疗药物通过特殊导管直接灌注肿瘤滋养动脉内，使肿瘤内的药物浓度比全身化疗时高数十倍，甚至数百倍；并能通过严格控制灌注药物的速度，使其与不同分期的肿瘤细胞充分接触，高效杀伤癌细胞；也为以往不能手术的患者创造再手术的机会，减少术后的复发，有效提高中晚期颅内恶性肿瘤的治愈率。我们对３０例原发和继发颅内恶性肿瘤进行免疫制剂和化疗药的联合应用，ＣＲ＋ＰＲ达到８０％以上，这一应用的推广在颅内恶性肿瘤治疗远期疗效上具有重要意义。
In recent years, with the development of interventional radiology technology, the super selective intra-arterial intubation of regional treatment of intracranial malignancies, including intracranial metastases, has been accepted by the majority of patients. This technique not only has simple operation and small trauma, but also applies to lesions of intracranial tumors in terms of depth, size, single or multiple, recurrence and metastasis after operation. More importantly, we use Pallier and chemotherapeutic drugs to directly infuse tumor nourish artery through special catheter so that the concentration of drug in the tumor is several times or even hundreds times higher than that of systemic chemotherapy. And we can strictly control the drug infusion Speed, make it fully contact with different stages of tumor cells, highly efficient killing of cancer cells; also in the past for patients with surgery to create the chance of reoperation, reduce postoperative recurrence, effectively improve the cure rate of advanced intracranial malignant tumors. We have 30 cases of primary and secondary intracranial malignant tumor immunotherapy and chemotherapy drug combination, CR + PR reached more than 80%, the promotion of this application in the long-term efficacy of intracranial malignant tumor treatment is of great significance.